

CITATION REPORT

List of articles citing

Sildenafil influences lower urinary tract symptoms

DOI: 10.1046/j.1464-410x.2002.03040.x
BJU International, 2002, 90, 836-9.

Source: <https://exaly.com/paper-pdf/34650540/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
228	Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. 2003 , 4, 488-96		31
227	[Therapy of erectile dysfunction in 2005]. 2003 , 42, 1330-6		3
226	Erektile DysfunktionEin Dauerbrenner. 2003 , 42, 1315-1316		4
225	Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). 2003 , 44, 637-49		838
224	Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction: focus on quality of life. 2003 , 63, 1947-62		16
223	New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction. 2003 , 123, 79-80		
222	Which is the association between erectile dysfunction and lower urinary tract symptoms?. 2004 , 36, 402-3		4
221	Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. 2004 , 1, 322-36		29
220	Round Table: New Frontiers in Sexual Medicine: L11: The Relationship between Erectile Dysfunction and Lower Urinary Tract Symptoms. 2004 , 1, 11-14		
219	[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors]. 2004 , 43, 820-8		9
218	The relationship between erectile dysfunction and lower urinary tract symptoms: Epidemiological, clinical, and basic science evidence. 2004 , 2, 71-77		
217	The relationship between erectile dysfunction and lower urinary tract symptoms: epidemiological, clinical, and basic science evidence. 2004 , 5, 251-7		63
216	Obstructive lower urinary tract symptoms correlate with erectile dysfunction. 2004 , 63, 1148-52		67
215	Association between lower urinary tract symptoms and erectile dysfunction. 2004 , 64, 772-6		86
214	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 185-196		
213	Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway?. <i>BJU International</i> , 2005 , 96, 250-3	5.6	6
212	Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). 2005 , 47, 824-37		156

211	Erectile dysfunction and lower urinary tract symptoms secondary to BPH. 2005 , 47, 838-45		165
210	The efficacy of tadalafil in clinical populations. 2005 , 2, 517-31		56
209	Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. 2005 , 2, 658-67		75
208	Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract--is there a basis for pharmacological targeting of cGMP?. 2005 , 23, 362-7		62
207	Inhibitory effects of sildenafil citrate on the tonus of isolated dog internal anal sphincter. 2005 , 48, 1615-9		7
206	Lower urinary tract symptoms and erectile dysfunction: epidemiology and treatment in the aging man. 2005 , 6, 445-53		13
205	Correlation between voiding and erectile function in patients with symptomatic benign prostatic hyperplasia. 2005 , 68, 178-82		6
204	Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. 2005 , 174, 205-9; discussion 209		39
203	LUTS and Sexual Dysfunction: What is the Link and How Can it Be Managed?. 2006 , 5, 722-728		0
202	Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice. 2006 , 38, 1-12		55
201	Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. 2006 , 38, 61-8		49
200	Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?. <i>BJU International</i> , 2006 , 97 Suppl 2, 39-43; discussion 44-5	5.6	45
199	Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. <i>BJU International</i> , 2006 , 98, 414-23	5.6	63
198	Potential future options in the pharmacotherapy of female sexual dysfunction. 2006 , 24, 630-8		7
197	Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. 2006 , 3, 662-667		112
196	Systemic nitric oxide augmentation leads to a rapid decrease of the bladder outlet resistance in healthy men. 2006 , 50, 112-7; discussion 117-8		14
195	Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. 2006 , 50, 1194-207; discussion 1207		74
194	Re: systemic augmentation of nitric oxide: is there an immediate effect on the urinary flow rate in healthy men?. 2006 , 76, 288		

193	Are lower urinary tract symptoms associated with erectile dysfunction in aging males of Taiwan?. 2006 , 77, 251-4		12
192	Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. 2007 , 19, 386-92		33
191	Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. 2007 , 19, 544-50		33
190	Characterization and functional role of androgen-dependent PDE5 activity in the bladder. 2007 , 148, 1019-29		192
189	Treating coexistent benign prostatic hyperplasia/lower urinary tract symptoms and erectile dysfunction in the aging male. 2007 , 3, 191-200		
188	Functional responses of isolated human seminal vesicle tissue to selective phosphodiesterase inhibitors. 2007 , 70, 185-9		28
187	Mechanism of Phosphodiesterase 5 inhibitor relief of prostatitis symptoms. 2007 , 69, 25-6		28
186	Phosphodiesterase type 5 inhibitors: state of the therapeutic class. <i>Urologic Clinics of North America</i> , 2007 , 34, 507-15, vi	2.9	23
185	Inhibidores de la fosfodiesterasa 5 y tracto urogenital. 2007 , 5, 73-81		
184	The Effects of Tamsulosin and Sildenafil in Separate and Combined Regimens on Detailed Hemodynamics in Patients With Benign Prostatic Enlargement. 2007 , 2007, 103-104		
183	Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. 2007 , 2007, 101-104		
182	Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. 2007 , 2007, 102-104		
181	Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. 2007 , 177, 1071-7		282
180	Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2007 , 177, 1401-7		292
179	Effects of Prostate Volume and Lower Urinary Tract Symptoms on Erectile Function. <i>Korean Journal of Urology</i> , 2007 , 48, 24		4
178	Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. 2007 , 26, 928-33		62
177	LUTS treatment: future treatment options. 2007 , 26, 934-47		116
176	Correlation between risk factors for vascular disease and the American Urological Association Symptom Score. <i>BJU International</i> , 2007 , 99, 97-100	5.6	26

175	An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. <i>BJU International</i> , 2007 , 100, 658-63	5.6	93
174	Effects of phosphodiesterase type 5 inhibitor on the contractility of prostate tissues and urethral pressure responses in a rat model of benign prostate hyperplasia. 2007 , 14, 946-51; discussion 951		24
173	Sildenafil citrate improves erectile function: a randomised double-blind trial with open-label extension. 2007 , 61, 1843-9		13
172	Male lower urinary tract symptoms and sildenafil. 2007 , 61, 1779		2
171	Results of double-blind placebo-controlled crossover study of sildenafil citrate (Viagra) in women suffering from obstructed voiding or retention associated with the primary disorder of sphincter relaxation (Fowler's Syndrome). 2007 , 51, 489-95; discussion 495-7		15
170	Phosphodiesterase type 5 inhibitors: the day after. 2007 , 51, 75-88; discussion 89		73
169	Re: Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. 2007 , 51, 278		
168	Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition. 2007 , 51, 772-80; discussion 780-1		34
167	Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. 2007 , 51, 1717-23		177
166	Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. 2007 , 52, 495-501		30
165	Editorial comment on: Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. 2007 , 52, 501-2		
164	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. 2007 , 52, 990-1005		45
163	Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. 2007 , 52, 1523-7		6
162	Immunohistochemical description of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human labia minora. 2007 , 4, 602-608		12
161	Influence of high-power potassium-titanyl-phosphate photoselective vaporization of the prostate on erectile function: a short-term follow-up study. 2007 , 4, 1701-7		33
160	In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. 2007 , 35, 49-54		53
159	[PDE5 inhibitors. A new option in the treatment of ureteral colic?]. 2007 , 46, 1219-23		18
158	The relationship between lower urinary tract symptoms (LUTS), diagnostic indicators of benign prostatic hyperplasia (BPH), and erectile dysfunction in patients with moderate to severely symptomatic BPH. 2008 , 40, 933-9		26

157	Lower urinary-tract symptoms and testosterone in elderly men. 2008 , 26, 359-64		52
156	The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. 2008 , 26, 603-9		76
155	The impact of phosphodiesterase inhibitors on lower urinary tract symptoms. 2008 , 6, 167-174		
154	Common approach to managing lower urinary tract symptoms and erectile dysfunction. <i>Asian Journal of Andrology</i> , 2008 , 10, 45-53	2.8	15
153	Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. 2008 , 15, 193-9		135
152	Medical treatments for benign prostatic hyperplasia and sexual function. <i>BJU International</i> , 2008 , 102 Suppl 2, 8-12	5.6	6
151	Pelvic ischemia is measurable and symptomatic in patients with coronary artery disease: a novel application of dynamic contrast-enhanced magnetic resonance imaging. 2008 , 5, 2635-45		17
150	Guide to drug therapy for lower urinary tract symptoms in patients with benign prostatic obstruction : implications for sexual dysfunction. 2008 , 68, 209-29		13
149	Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. 2008 , 71, 526-30		64
148	Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. 2008 , 42, 111-5		15
147	Estudio prospectivo para valorar el impacto del sildenafil 50 mg/día durante 28 días en pacientes con disfunción eréctil y sintomatología secundaria a hiperplasia benigna de próstata. 2008 , 6, 84-88		1
146	Voiding Function and Dysfunction, Bladder Physiology and Pharmacology, and Female Urology. 2008 , 179, 622-623		
145	Phosphodiesterase-5 inhibitors in the treatment of lower urinary tract symptoms and benign prostatic hyperplasia. 2008 , 9, 1687-93		10
144	Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement?. 2008 , 80, 181-5		20
143	Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. 2008 , 11, 51-5		32
142	A survey of commonalities relevant to function and dysfunction in pelvic and sexual organs. 2008 , 20, 1-16		10
141	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , 2008 , 5, 355-365		2
140	Association between Lower Urinary Tract Symptoms and Erectile Dysfunction in Aging Men: Hallym Aging Study. <i>Korean Journal of Urology</i> , 2008 , 49, 633		4

139	Microvascular complications in diabetic erectile dysfunction: do we need other alternatives?. 2009 , 32 Suppl 2, S420-2	7
138	Phosphodiesterase type 5 inhibitors: a viable treatment option for lower urinary tract symptoms?. 2009 , 18, 245-54	1
137	PDE5 inhibitors for LUTS. 2009 , 12, 316-24	22
136	Prospective pharmacologic therapies for the overactive bladder. 2009 , 1, 71-83	34
135	Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. 2009 , 6, 544-52	89
134	Increased sexual dysfunction in men with storage and voiding lower urinary tract symptoms. 2009 , 6, 1103-1110	30
133	Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. 2009 , 6, 836-47	33
132	Vardenafil modulates bladder contractility through cGMP-mediated inhibition of RhoA/Rho kinase signaling pathway in spontaneously hypertensive rats. 2009 , 6, 1594-1608	70
131	Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function. 2009 , 6, 2299-304	34
130	The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. 2009 , 6, 3158-65	27
129	The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. 2009 , 55, 38-48	69
128	Open to debate. The motion: PDE5 inhibitors are a promising therapy for benign prostatic hyperplasia. 2009 , 56, 878-80	2
127	ERG evaluation of daily, high-dose sildenafil usage. 2009 , 118, 225-31	23
126	Uroflowmetric assessment of acute effects of sildenafil on the voiding of men with erectile dysfunction and symptomatic benign prostatic hyperplasia. 2009 , 41, 287-92	19
125	The burden and extent of comorbid conditions in patients with erectile dysfunction. 2009 , 63, 1205-13	42
124	Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. 2009 , 41, 7-13	67
123	Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. <i>BJU International</i> , 2009 , 103, 987-90	5.6 22
122	The effect of sildenafil citrate on bladder outlet obstruction: a mouse model. <i>BJU International</i> , 2009 , 104, 252-6	5.6 33

121	Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?. <i>BJU International</i> , 2009 , 104, 511-7	5.6	19
120	Relaxant effects of sildenafil on the human isolated bladder neck. 2009 , 73, 427-30		23
119	Vardenafil: efficacy, tolerability and future directions. 2009 , 5, 553-62		3
118	Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. 2009 , 19, 380-94		143
117	Phosphodiesterase type 5 inhibitors: unmet needs. 2009 , 15, 3476-85		25
116	Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. 2010 , 20, 49-54		38
115	Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats. 2010 , 42, 53-6		10
114	Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. 2010 , 7, 59-69		109
113	Detrusor myocyte activity and afferent signaling. 2010 , 29, 97-106		75
112	The effect of transurethral resection of the prostate on erectile function in patients with benign prostatic hyperplasia. <i>Korean Journal of Urology</i> , 2010 , 51, 557-60		12
111	Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. 2010 , 13, 242-6		45
110	Clinical Andrology. 2010 ,		1
109	[Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article]. 2010 , 20, 616-26		2
108	Phosphodiesterase Type 5 Inhibitors for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia. 2010 , 21, 2-7		
107	Vardenafil effect on ureteric smooth muscle: in vitro study in porcine model. 2011 , 25, 505-9		8
106	Physiology and Pharmacology of the Bladder. 2011 , 123-138		
105	Urinary Tract. 2011 ,		7
104	Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options. 2011 , 9, 147-52		12

103	Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors. 2011 , 307-22		8
102	Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. <i>BJU International</i> , 2011 , 107, 1104-9	5.6	34
101	Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. 2011 , 72, 197-204		43
100	Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH). 2011 , 163, 891-907		51
99	Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. 2011 , 60, 527-35		42
98	The medical treatment of overactive bladder, including current and future treatments. 2011 , 12, 1041-55		10
97	Update on the sexual impact of treatment for benign prostatic hyperplasia. 2012 , 13, 433-40		12
96	Evaluation and Medical Management of BPH and LUTS in Men. 2012 , 55-65		
95	Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication. 2012 , 38, 33-9		9
94	Les inhibiteurs de la phosphodiesterase de type 5 : une révolution dans le traitement des symptômes du bas appareil urinaire?. 2012 , 22, 80-91		1
93	A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α -blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. 2012 , 61, 994-1003		212
92	Phosphodiesterase Type 5 Inhibitor and Erectile Dysfunction in Lower Urinary Tract Symptoms. 2012 , 4 Suppl 1, 75-80		2
91	Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. 2012 , 44 Suppl 1, 791-5		17
90	Monotherapy for comorbid erectile dysfunction and lower urinary tract symptoms: phosphodiesterase inhibitor or α -adrenoceptor antagonist?. <i>BJU International</i> , 2012 , 109, 965-6	5.6	1
89	PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. 2013 , 8, 150-159		12
88	Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. 2013 , 45, 39-43		42
87	The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. 2013 , 14, 585-94		17
86	[Effects of phosphodiesterase type 5 inhibitors on lower urinary tract symptoms secondary to benign prostatic hyperplasia]. 2013 , 23, 283-95		3

85	Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. 2013 , 47, 278-83		13
84	Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. 2013 , 33, 639-49		16
83	The role of phosphodiesterases in bladder pathophysiology. 2013 , 10, 414-24		22
82	Tadalafil significantly reduces ischemia reperfusion injury in skin island flaps. 2013 , 46, 75-81		14
81	The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. 2013 , 39, 264-9		
80	Improvement of erectile function in patients with benign prostatic hyperplasia undergoing transurethral plasmakinetic resection of the prostate. 2013 , 20, 724-8		5
79	Distribution of phosphodiesterase type 5 (PDE5) in the lateral wall of the guinea pig urinary bladder. <i>BJU International</i> , 2013 , 112, 246-57	5.6	12
78	Effects of chronic administration of tamsulosin and tadalafil, alone or in combination, in rats with bladder outlet obstruction induced by chronic nitric oxide deficiency. 2014 , 40, 546-52		3
77	Does sildenafil enhance the effect of tamsulosin in relieving acute urinary retention?. 2014 , 40, 373-8		7
76	. 2014 ,		
75	WITHDRAWN: Effect of phosphodiesterase inhibitors in the bladder. 2014 ,		
74	Effects of phosphodiesterase type 5 inhibitor, tadalafil, on continence reflex in rats. 2014 , 25, 1721-7		5
73	Landmarks in BPH--from aetiology to medical and surgical management. 2014 , 11, 118-22		10
72	Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?. 2014 , 24, 21-8		39
71	The Use of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. 2014 , 113-128		
70	Male LUTS/BPH Made Easy. 2014 ,		
69	Pharmacological approach to overactive bladder and urge urinary incontinence in women: an overview. 2014 , 174, 27-34		12
68	New Medical and Injectable Treatments for LUTS/BPH Anticholinergics, PDE-5, and Botox. 2014 , 9, 114-121		1

67	Neural control of lower urinary tract and targets for pharmacological therapy. 2014 , 25, 1453-62		8
66	Influence of sildenafil on blood oxygen saturation of the obstructed bladder. 2014 , 14, 44		7
65	Upregulation of Phosphodiesterase type 5 in the Hyperplastic Prostate. 2015 , 5, 17888		16
64	Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α -adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. <i>Asian Journal of Andrology</i> , 2015 , 17, 1022-32	2.8	15
63	Evoluci3n en el tratamiento m3dico de los s3ntomas del tracto urinario bajo en hombres. 2015 , 75, 30-37		
62	Gu3a de manejo de la hiperplasia prost3tica benigna. Sociedad Colombiana de Urolog3a 2014. 2015 , 24, 187.e1-187.e32		1
61	Effect of phosphodiesterase inhibitors in the bladder. 2015 , 2, 33-37		5
60	New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is). 2016 , 23, 1239-49		27
59	Korean clinical practice guideline for benign prostatic hyperplasia. 2016 , 57, 30-44		27
58	Antimuscarinics, β Agonists, and Phosphodiesterase Inhibitors in the Treatment of Male Lower Urinary Tract Symptoms: An Evolving Paradigm. <i>Urologic Clinics of North America</i> , 2016 , 43, 337-49	2.9	3
57	The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms. <i>BJU International</i> , 2016 , 118, 313-9	5.6	1
56	Sexual Dysfunction Related to Drugs: a Critical Review. Part V: β -Blocker and 5-ARI Drugs. 2016 , 49, 3-13		29
55	Daily use of sildenafil 50mg at night effectively ameliorates nocturia in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: an exploratory multicenter, double-blind, randomized, placebo-controlled study. 2017 , 20, 81-88		9
54	Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. 2017 , 13, 183-192		19
53	Chronic Administration of Tadalafil Improves the Symptoms of Patients with Amicrobic MAGI: An Open Study. 2017 , 2017, 3848545		2
52	Xybilun 3 , actualit320183de la dysfonction fectile. 2018 , 27, 67-71		
51	PDE5 inhibitors - pharmacology and clinical applications 203years after sildenafil discovery. 2018 , 175, 2554-2565		170
50	Treatment of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. 2018 , 21, 272-280		9

49	Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia. 2018 , 11, CD010060		8
48	Medical Therapy for Benign Prostatic Hyperplasia. 2018 , 9-22		
47	Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Erectile Dysfunction. 2018 , 51-88		
46	Efficacy and safety of PDE5-Is and α_1 blockers for treating lower ureteric stones or LUTS: a meta-analysis of RCTs. 2018 , 18, 30		5
45	The global prevalence of erectile dysfunction: a review. <i>BJU International</i> , 2019 , 124, 587	5.6	59
44	Treatment of experimentally induced benign prostatic hyperplasia with Tadalafil and castration in dogs. 2020 , 142, 236-245		4
43	Changes in the expression and function of the PDE5 pathway in the obstructed urinary bladder. 2020 , 24, 13181-13195		2
42	Phosphodiesterase type 5 inhibitor therapy provides sustained relief of symptoms among patients with chronic pelvic pain syndrome. 2020 , 9, 391-397		4
41	The nitric oxide-cyclic guanosine monophosphate pathway inhibits the bladder ATP release in response to a physiological or pathological stimulus. 2021 , 9, e14938		1
40	The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms. 2021 , 81, 944-955		1
39	Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α_1 Blockers and 5-Alpha Reductase Inhibitors. 2021 , 1, 82-98		
38	Medical Treatment of LUTS/BPH. 2014 , 67-87		3
37	Current Pharmacologic Treatment of Lower Urinary Tract Symptoms. 2014 , 121-222		1
36	Cyclic nucleotide metabolism including nitric oxide and phosphodiesterase-related targets in the lower urinary tract. 2011 , 527-42		17
35	Pharmacologic Management of Lower Urinary Tract Storage and Emptying Failure. 2012 , 1967-2002.e14		3
34	Evaluation and Nonsurgical Management of Benign Prostatic Hyperplasia. 2012 , 2611-2654.e8		7
33	Combination therapy for erectile dysfunction: an update review. <i>Asian Journal of Andrology</i> , 2011 , 13, 382-90	2.8	24
32	Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. 2006 , 16, 11-19		38

31	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. 2006 , 1, 403-14		36
30	Recent advances in management of bladder overactivity. 2010 , 2,		3
29	Bladder Pharmacology and Treatment of Lower Urinary Tract Symptoms: Recent Advances. 2008 , 01,		2
28	Clinical and preclinical treatment of urologic diseases with phosphodiesterase 5 inhibitors: an update. <i>Asian Journal of Andrology</i> , 2016 , 18, 723-31	2.8	8
27	The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors. <i>Central European Journal of Urology</i> , 2014 , 67, 314-8	0.9	7
26	Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction. <i>Medicinski Arhiv = Medical Archives = Archives De Médecine</i> , 2017 , 71, 32-36	1.2	4
25	Drugs and future candidates. <i>Canadian Urological Association Journal</i> , 2011 , 5, S131-3	1.2	8
24	Role of Phosphodiesterase Type 5 Inhibitor on Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms. <i>Korean Journal of Andrology</i> , 2011 , 29, 91		1
23	Overactive bladder syndrome and the potential role of prostaglandins and phosphodiesterases: an introduction. <i>Nephro-Urology Monthly</i> , 2013 , 5, 934-45	0.4	19
22	Sildenafil citrate: a 5-year update on the worldwide treatment of 20 million men with erectile dysfunction. 2004 , 35-47		
21	Drug Interaction Study of Vardenafil 20mg and Doxazosin 4mg or Tamsulosin 0.2mg in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction to Evaluate Changes in Blood Pressure. <i>Korean Journal of Urology</i> , 2006 , 47, 1001		
20	Changes in Corpus Cavernosum after Partial Bladder Outlet Obstruction in Rat. <i>Korean Journal of Urology</i> , 2008 , 49, 160		
19	Improvement of Lower Urinary Tract Symptoms and Sexual Function after Treatment with Alpha-Blocker. <i>Korean Journal of Urology</i> , 2009 , 50, 369		1
18	Drug Treatment of Voiding Dysfunction in Women. 2010 , 418-446		
17	Pharmacology of the Bladder. 2010 , 212-226		
16	Non-Hormonal treatment of BPH/BOO. <i>Indian Journal of Urology</i> , 2014 , 30, 194-201	0.8	1
15	Medical Management of Benign Prostatic Hyperplasia. 2020 , 21-42		0
14	Do AB0 blood groups affect lower urinary tract symptoms?. <i>Turkish Journal of Urology</i> , 2019 , 45, S84-S91.	1.3	

13	The Study of Tadalafil and Tamsulosin as Monotherapy for Lower Urinary Tract Symptoms Due to Benign Hyperplasia of Prostate. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2019 , 8, 3968-3971	0.1	
12	Physiology and Pharmacology of the Prostate. 2020 , 127-150		1
11	Tadalafil: a long-acting PDE5 inhibitor for the management of erectile dysfunction. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 185-196		
10	Medical therapy for benign prostatic hyperplasia: new terminology, new concepts, better choices. <i>Reviews in Urology</i> , 2006 , 8, 14-22	1	6
9	Lower urinary tract symptoms, benign prostatic hyperplasia, erectile dysfunction, and phosphodiesterase-5 inhibitors. <i>Reviews in Urology</i> , 2004 , 6, 121-7	1	15
8	Best of the 2004 AUA Annual Meeting: Highlights from the 2004 Annual Meeting of the American Urological Association, May 8-13, 2004, San Francisco, CA. <i>Reviews in Urology</i> , 2004 , 6, 128-60	1	
7	Sexual Function and alpha-Blockers. <i>Reviews in Urology</i> , 2005 , 7 Suppl 8, S3-S11	1	2
6	Best of the 2006 AUA Annual Meeting: Highlights from the 2006 Annual Meeting of the American Urological Association, May 20-25, 2006, Atlanta, GA. <i>Reviews in Urology</i> , 2006 , 8, 120-64	1	
5	Update on Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia. <i>Reviews in Urology</i> , 2012 , 14, 79-86	1	2
4	Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study. <i>Indian Journal of Urology</i> , 2019 , 35, 25-33	0.8	1
3	Medical Treatment of Benign Prostatic Hyperplasia.. <i>Urologic Clinics of North America</i> , 2022 , 49, 231-238	2.9	0
2	Comparison of Tamsulosin and Tadalafil effects in LUTS treatment considering patientsT atherosclerosis risk level. <i>Annals of Medicine and Surgery</i> , 2022 , 80, 104137	2	
1	Updates on androgen replacement therapy and lower urinary tract symptoms: a narrative review. 2022 , 25, 234-241		0